Contracts › 75D30124C18761
75D30124C18761: Mpox Immunogenicity and Seroprevalence
Awarded to University of California, Los Angeles by Centers for Disease Control and Prevention (CDC).
$4.2Mobligated
$4.3Mpotential value
02 September 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75D30124C18761 |
|---|---|
| Awardee | University of California, Los Angeles |
| Awarding agency | Centers for Disease Control and Prevention (CDC) |
| Awarding office | CDC OFFICE OF ACQUISITION SERVICES |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN23 Health R&D Services; Health Research and Training; Experimental Development |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 03 September 2024 to 02 September 2028 |
| Potential end | 02 September 2028 |
| Estimated recompete solicitation | ~Q1 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record